Improvement of Women's Health After Allogeneic Stem Cell Transplantation
Ciusss de L'Est de l'Île de Montréal
100 participants
Aug 27, 2024
OBSERVATIONAL
Conditions
Summary
The aim of this prospective research project is to better understand vulvovaginal cGVHD to improve care of allografted women. The expected outcomes include better knowledge of the incidence and manifestations of vulvovaginal cGVHD, risk factors, response to treatments and impact on sexual health of allotransplanted female patients. The knowledge acquired will allow transplant clinicians to make more precise recommendations for gynecological management of future allografted women.
Eligibility
Inclusion Criteria1
- All women aged 18 and over who will receive a first allogeneic HSCT (bone marrow, peripheral blood stem cells from a related, unrelated (including cord blood) or haploidentical donor) at the CIUSSS-EMTL. Recruitment will begin when the project receives ethical approval. Recruitment period will be of 2 to 3 years.
Exclusion Criteria5
- Those who receive a second HSCT allograft.
- Those who receive an autologous transplant.
- Inability to give informed consent.
- Unable to communicate in French or English.
- Any other reason which, according to the investigators, makes it preferable for a patient not to participate.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06279676